AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02556931 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Day -1: 200 cGy in a single fraction
Study NCT02556931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.
Study NCT02556931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
Study NCT02532140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5107 250 mg to 2000 mg
Study NCT02532140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime 2000 mg
Study NCT02532140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5107 1000/2000 mg with Cefepime 2000 mg combination
Study NCT02532140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00654446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT00654446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study NCT00287352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine, Amantadine
Description: Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
Study NCT00287352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine and placebo
Description: Olanzapine continuing as clinically indicated
Study NCT02229487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance
Study NCT02229487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance
Study NCT02264301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Puerarin injection 400 mg
Study NCT02264301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingkailing injection 40 ml
Study NCT01058876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated nicotine and cotinine
Description: used as a marker for pharmacokinetic studies
Study NCT01319305 — intervention group
Intervention type: DEVICE
Intervention: FinESS Sinus Treatment
Description: balloon sinuplasty
Study NCT03543046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tortle Midliner
Description: The Tortle Midliner will be applied in the treatment group within the first 3 hours of life and maintained until 72 hours of life.
Study NCT03869684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-0814
Description: Randomly assigned dose
Study NCT03869684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo manufactured to mimic MT-0814
Study NCT04553731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: empowerment program with mHealth
Description: empowerment program with mHealth
Study NCT01170429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaterol hydrochloride
Description: 25µg BID for 8 weeks
Study NCT01170429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meptin placebo
Description: 25µg BID for 8 weeks
Study NCT00778817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Given IV
Study NCT00778817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitotane
Description: Given orally
Study NCT03869684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo manufactured to mimic MT-0814
Study NCT02414074 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Youth Behavioral Intervention
Description: Teen Intervene is an early intervention program for 12-19 year olds.
Study NCT02925481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Online yoga participation
Description: Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 150 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
Study NCT02925481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and toning
Description: Phase 1: Developing 12 week prescription for online control videos Phase 2: Online streaming stretching and toning videos completed at home which consist of a warm-up, 1 balance, 2 core, 2-3 upper body and lower body exercises, 6 stretches, cool-down
Study NCT02925481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose online yoga participation
Description: Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 60 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
Study NCT03374865 — intervention group
Intervention type: OTHER
Intervention: Facetalk
Description: Area of interest: communication during Facetalk consultations
Study NCT02414074 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Education
Description: Everyday Parenting is a parent training curriculum.
Study NCT00720473 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lamotrigine
Description: Lamotrigine with dosage range from 25 mg to 200 mg per day.
Study NCT04403191 — intervention group
Intervention type: DRUG
Intervention: Ondansetron
Description: ondansetron 4 mg intravenous immediately once reached to I.C.U and another same dose after 6 hours while patients of group
Study NCT04403191 — intervention group
Intervention type: DRUG
Intervention: isopropyl alcohol 70% inhalation
Description: inhalation every 15 min for 4 times then repeated after 6 hours
Study NCT04403191 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy
Description: all patients received post operatively after laparoscopic appenectomy
Study NCT04441801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position
Study NCT04441801 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stretching exercise
Description: Static stretching consists of stretching a muscle (or group of muscles) to its farthest point and then maintaining or holding that position
Study NCT03374865 — intervention group
Intervention type: OTHER
Intervention: Face-to-face consultation
Description: Area of interest: communication during face-to-face consultations
Study NCT02571673 — intervention group
Intervention type: BEHAVIORAL
Intervention: Assessments
Description: Usability outcomes will come from patient surveys and interviews and a nurse practitioner interview in Aim 1: Part 1. In Aim 1: Part 2, patients and their primary care providers will complete online surveys regarding feasibility. Health outcomes and data regarding health care actions will be collected from HN-STAR and the clinic note will be collected to assess feasibility of collecting these metrics in a future trial. Directly after each clinic visit, the NP will complete one brief online survey for each participant.
Study NCT02200822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAAS blockers
Description: RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
Study NCT02756624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24%
Study NCT02756624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 Vehicle
Study NCT02783586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block type II
Description: Local anaesthetic injection on the posterior border of the quadratus lumborum muscle
Study NCT02783586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominalis Plane Block
Description: Local anaesthetic injection between internal oblique and transversus abdominis muscle
Study NCT02783586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 ml of bupivacaine with adrenaline
Study NCT02783586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of bupivacaine with adrenaline
Study NCT02783586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultraplex
Description: A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
Study NCT04217031 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00712660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antipsychotic dose increase
Description: 20% increase in the dose of current antipsychotic medication
Study NCT00712660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: Treatment as usual
Study NCT04622618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Anticonvulsant, Antiemetic, Analgesic
Study NCT03799757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40ml of 0.25% bupivacaine
Study NCT03799757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 40ml of 0.9% normal saline
Study NCT04977089 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lipid profile test .
Description: Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
Study NCT04530188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
Study NCT04530188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous sedation with propofol, as already used in our ICU
Study NCT03207815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally
Study NCT00840788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: octyl-2-cyanoacrylate adhesive glue
Description: use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
Study NCT00840788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular suture of perineal skin
Description: Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
Study NCT04768491 — intervention group
Intervention type: DRUG
Intervention: Dacomitinib
Description: effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
Study NCT03207815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally
Study NCT02783586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultraplex
Description: A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
Study NCT01748916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papaya
Description: Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
Study NCT01748916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carrot
Description: Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
Study NCT00425516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Study NCT00425516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Study NCT00425516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT00425516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02791711 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High Flow Nasal Cannula
Description: Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
Study NCT02022410 — intervention group
Intervention type: OTHER
Intervention: CAS after primary and revision TKA
Description: CAS and RAPT
Study NCT01748916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
Study NCT02720705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: oral dexmedetomidine
Study NCT02720705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 2ml 0.9% saline administered orally half an hour before induction of anesthesia
Study NCT00557518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alagebrium
Description: 200 mg bid
Study NCT00557518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: bid
Study NCT01442207 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a Cervical Cerclage
Description: Surgical placement of a cervical cerclage
Study NCT01442207 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Expectant Management
Description: Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~* Standard management for placenta previa.~* Hospital admission for vaginal bleeding/hemorrhage~* Antenatal corticosteroids > 24w0d of gestation~* Tocolytic therapy per physician's discretion~* Magnesium sulfate for neuroprotection~* Fetal Heart Rate Monitoring~* Avoidance of digital examinations of the cervix~* Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM > 34 wks, worsening maternal or fetal condition )~* Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound.
Study NCT02409888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: The motivational enhancement therapy will be delivered according to the Project MATCH manual.
Study NCT00318006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: saline irrigation
Description: subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
Study NCT00318006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saline spray
Description: subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
Study NCT04481256 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
Study NCT04481256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
Study NCT04481256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
Study NCT04481256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
Study NCT00002774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirapazamine
Description: Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.~Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.~Tirapazamine dose was as follows:~Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)~Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)~Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)
Study NCT00002774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
Study NCT00002774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
Study NCT00002774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT.
Study NCT00002774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT.
Study NCT00002774 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy (RT)
Description: During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery.
Study NCT00002774 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery.
Study NCT00892424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
Study NCT02258607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Description: Momelotinib (MMB) tablet(s) administered orally once or twice daily
Study NCT02258607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib tablet administered orally once daily
Study NCT01020773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: spontaneous breathing trial
Study NCT01020773 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: spontaneous breathing trial